B cell immunotherapy

A technology of B cells and cells, applied in the field of B cell immunotherapy, can solve the problem of expensive treatment

Pending Publication Date: 2021-11-19
THE GENERAL HOSPITAL CORP
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the suggested treatments are often very expensive and involve significant risks and complications

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • B cell immunotherapy
  • B cell immunotherapy
  • B cell immunotherapy

Examples

Experimental program
Comparison scheme
Effect test

example

[0274] The present invention is described in further detail in the following examples, which are in no way intended to limit the scope of the claimed invention. The accompanying drawings are intended to be considered as an integral part of the specification and description of the invention. All references cited are expressly incorporated by reference for all content described herein. The following examples are offered to illustrate, not limit, the claimed invention.

example 1

[0275] Example 1: Exogenous B Cells Modulate Immune Infiltration and Response

[0276] This example illustrates the large-scale analysis of the molecular impact of B cells in wound healing using isobaric labeling multiplex proteomics.

[0277] Our data show that B cell imposition has a dramatic homeostatic effect on the wound microenvironment, with significant reductions in proteins associated with inflammatory responses and increases in proteins associated with tissue growth and remodeling. By recovering applied exogenous B cells from the wound microenvironment at various time points after application, and examining cell populations by multicolor flow cytometry, we determined that mature naive B cells applied to wounds transitioned to be characterized by expression of CD138 and regulatory phenotypes of the immunomodulatory cytokines IL-10, IL-35, and TGF-β. This Breg-like phenotype was transient, with a peak at day 2 post application. In addition, the phenotype of monocytes...

example 2

[0327] Example 2: B cell treatment improves outcome after TBI

[0328] This example demonstrates that exogenously administered B cells significantly improve post-injury performance in a mouse TBI model.

[0329] Brain contusion results in neurological dysfunction, mediated in part by the inflammatory response to injury. B lymphocytes are dynamic regulators of the immune system and have not been systematically studied in TBI. Using a mouse model of controlled cortical impingement (CCI), we assessed the possible beneficial effects of exogenously applied B cells on histopathological and functional outcomes after TBI. Inject 2×10 mice into the brain parenchyma of the lesion 6 mature naive isogenic splenic B cells, followed by CCI. Control CCI mice received equal amounts of T cells or saline, and sham-injured mice (craniotomy only) were given B cells or saline. The sham-injury group performed similarly on the motor and learning tests. Injured mice administered B cells showed sig...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention, in general, features a method of treating a neurodegenerative disease (such as amyotrophic lateral sclerosis) or a traumatic brain injury in a subject (e.g., a human) in need thereof, the method comprising administering to the subject a therapeutically effective amount of isolated B cells (such as autologous or allogeneic or xenogeneic B cells).

Description

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS [0002] This application claims U.S. Provisional Application No. 62 / 798,629, filed January 23, 2019, U.S. Provisional Application No. 62 / 837,765, filed April 24, 2019, and U.S. Provisional Application No. 62 / 965,032, filed January 23, 2020 interests, the contents of which are incorporated herein by reference in their entirety. Background technique [0003] Degenerative diseases are medical conditions that result in the degeneration of cells, tissues or organs. For example, amyotrophic lateral sclerosis (ALS), Parkinson's disease (PD), Alzheimer's disease (AD), and Huntington's disease (HD) are among the numerous neurodegenerative diseases involving degeneration of regions of the central nervous system. Traumatic brain injury (TBI) is also an example of a disorder that may increase the risk of developing a degenerative brain disease such as PD or AD. Rheumatoid arthritis and osteoarthritis are still other examples of degenerati...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K35/17A61P25/28A61P25/16A61P25/14C12N5/0781
CPCA61P25/28A61K2239/31A61K2239/26A61K39/4622A61K2239/38A61K39/46432A61K39/4611A61K39/46433A61K39/4612A61K39/4621
Inventor 马克·C·波兹南斯基鲁克桑德拉·F·西尔布列斯库
Owner THE GENERAL HOSPITAL CORP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap